Navigation Links
Takeda Launches New Subsidiary in Peru
Date:8/22/2013

ZURICH, August 22, 2013 /PRNewswire/ --

Demonstrates Takeda's long-term commitment to the Latin American market

Takeda Pharmaceuticals International GmbH ("Takeda") today announced further expansion of its presence in Latin America with the launch of a wholly-owned subsidiary in Peru. Takeda Peru S.R.L. (Takeda Peru or "the Company") will be headquartered in Lima and will be responsible for the sales and marketing of Takeda's products in Peru.

Takeda is building a leading position in Latin America. It has a direct presence in Brazil, Mexico, Argentina, Venezuela, Colombia, Ecuador and now Peru, and is looking at opportunities to further expand its footprint in the region. According to IMS Market Prognosis, pharmaceutical sales in those countries totaled US$60 billion in 2012 and are expected to grow at a compound annual rate of 12.5%* between 2013 and 2017. Takeda plans to outgrow the market over the same period.

Peru is a dynamic and growing market, driven by government investment and strong mining industries. It is estimated that the country's GDP totaled US$ 200 billion in 2012 while pharmaceutical sales amounted to US$1.5 billion and are expected to continue to grow by 8% during 2013*.

In line with Takeda's emerging markets strategy, Takeda Peru is building a product portfolio based on the medical needs of the population, focusing on gastroenterology, cardiology, metabolism, oncology and respiratory diseases. The Company will initially focus on Zurcal (pantoprazole), Riopan (Magaldrate + Dimeticone) Faktu (Policresulen, Cinchocaine hydrochloride), and its gynaecology product, Albothyl (Policresulen), which Takeda repatriated following the Nycomed acquisition.

Takeda plans to leverage its Peru sales platform with a steady stream of product launches from its existing portfolio and R&D pipeline.

Julio Cesar Acevedo Orrego has been appointed country manager for Peru. He joins the organization from Takeda Colombia, where he has built up and headed the Takeda Sales and Marketing organization following the acquisition of Farmacol Laboratories. He will lead the start-up team which will grow steadily as the Company expands its portfolio and enters new therapeutic areas.

"The launch of our subsidiary in Peru reinforces Takeda's position in Latin America and will enable us to meet the diverse healthcare needs of the population. We have an established product portfolio, which will give us a strong starting point and we look forward to launching our novel medicines into the market," said Norbert Oppitz, Senior Vice President, Latin America, at Takeda. "This investment further demonstrates our commitment to Latin America and its growth potential."

[*]Data Source:© 2012 IMS Health. All rights reserved. Estimate based on Market Prognosis Global 2012-2016.  

About Takeda Pharmaceuticals International GmbH

Headquartered in Zurich as a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Osaka, Japan, the company has a commercial presence covering more than 70 countries, with particular strength in Asia, North America, Europe and fast-growing emerging markets including Latin America, Russia-CIS and China. Areas of focus include cardiovascular and metabolic, oncology, respiratory and immunology, central nervous system, general medicine, and vaccines.

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Through the integration of Millennium Pharmaceuticals and Nycomed, Takeda has been transforming itself, broadening its therapeutic expertise and geographic outreach.

Additional information about Takeda is available through its corporate website, http://www.takeda.com.

This press release has been issued by Takeda Pharmaceuticals International GmbH, Thurgauerstrasse 130, CH-8152 Glattpark-Opfikon, Zurich, Switzerland.


'/>"/>
SOURCE Takeda Pharmaceuticals International GmbH
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
2. Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceuticals Brintellix Has Blockbuster Potential
3. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
4. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
5. AGA Research Foundation Announces Endowment Gift from Takeda Pharmaceuticals U.S.A., Inc. to Support Gastroenterology Research
6. Takeda to Acquire Inviragen, Inc.
7. Takeda Responds to Verdict in Diabetes Drug Case
8. Takeda Launches New Subsidiary in Ecuador
9. Takeda lanza nueva subsidiaria en Ecuador
10. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
11. Takeda presenta la richiesta di autorizzazione allimmissione in commercio nellUnione Europea per Vedolizumab nella colite ulcerosa moderata-grave e nella malattia di Crohn
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
(Date:6/23/2016)... 2016 Bracket , a leading clinical trial ... clinical outcomes platform, Bracket eCOA (SM) 6.0, at the ... – 30, 2016 in Philadelphia , Pennsylvania.  ... Assessment product of its kind to fully integrate with RTSM, ... eCOA 6.0 is a flexible platform for electronic clinical outcomes ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop ... The fitness app plans to fix the two major problems leading the fitness industry today:, ... all type program , They don’t eliminate all the reasons people quit their ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
Breaking Medicine News(10 mins):